Global spinal cord trauma market to grow at 3.7% CAGR through 2025: 5 observations

Written by Megan Wood | November 14, 2017 | Print  |

The global spinal cord trauma market is set to grow at a 3.7 percent compound annual growth rate through 2025, according to a Market Research Reports Search Engine analysis.

Here are five observations:


1. Nerve cell growth therapy will serve as a driver for the global market.


2. The partial spinal cord injury sector will likely grow at a higher rate than the complete SCI segment.


3. Hospitals accounted for a 53.2 percent market share in 2017, but will likely drop to 52.5 percent by 2025.


4. Road accidents and crime will drive spinal cord trauma treatment market in the Asia-Pacific area.


5. Bioaxone Biosciences, Acorda Therapeutics, Kringle Pharma, Pfizer, Novartis, Vertex Pharmaceuticals, InVivo Therapeutics, BioArctic, Asterias Biotherapeutics, Pharmicell, ReNetX Bio and BioTime will lead the market.


More articles on devices:
Eliminating the 'price of doing business': How Olympus' ORBEYE is minimizing surgeon fatigue during spine surgery
SpineGuard, XinRong launch PediGuard in China: 5 key points
Artificial joints market to see 5.53% CAGR through 2021: 4 insights

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months